Lonza Revenue and Competitors
Employee Data
- Lonza has 19337 Employees.
- Lonza grew their employee count by 4% last year.
Lonza's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Human Resources Officer | Reveal Email/Phone |
3 | Executive Director, Global Head Business Development, Cell & Gene Therapy | Reveal Email/Phone |
4 | CIO Office Assistant | Reveal Email/Phone |
5 | Chief Staff and Strategic Initiatives for the CIO | Reveal Email/Phone |
6 | Chief Staff | Reveal Email/Phone |
7 | Global VP, Product Management and Marketing | Reveal Email/Phone |
8 | CEO Lonza Group | Reveal Email/Phone |
9 | Executive Director Corporate Accounting & Controlling Concepts | Reveal Email/Phone |
10 | Executive Director, Global Head Account Management, Cell & Gene | Reveal Email/Phone |
Lonza Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1629.4M | 3581 | N/A | N/A | N/A |
What Is Lonza?
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients, both chemically and biologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion.
keywords:N/A
N/A
Total Funding
19337
Number of Employees
N/A
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lonza News
Lonza's 14 years of expertise in in silico and in vitro immunogenicity and immunotoxicity assessments complements Integral Molecular's valuable...
Pharmaceutical manufacturing company Lonza has announced the completion of the laboratory expansion at its active pharmaceutical ingredients...
Lonza Joins International Pharmaceutical Aerosol Consortium on Regulation & Science. Will collaborate with other industry leaders to advance the...
Press Release | Nov 10. 2021 07:07 GMT SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate and Chr. Hansen. ...
Lonza will expand its drug development in Switzerland yet again with investments in three of its manufacturing sites, the company announced Wednesday, capping off a very busy year for the Euro giant. The expansion will feature the addition of an aseptic filling line for clinical supply of drug ...
Other Companies in Morristown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4898.9M | 34992 | 14% | N/A |